Duke Cancer Institute
One of the original NCI comprehensive centres (1973), famous for brain tumour research including the polio-virus immunotherapy for glioblastoma.
Duke has held NCI comprehensive designation since 1973. The Preston Robert Tisch Brain Tumor Center, built by Darell Bigner, developed the recombinant polio-rhinovirus PVSRIPO oncolytic immunotherapy for recurrent glioblastoma and, with Hai Yan, helped define IDH mutations in glioma. Duke investigators helped lead pivotal HER2 breast cancer trials including EMILIA (trastuzumab emtansine), and its prostate programme (Andrew Armstrong, Daniel George) is a fixture of Alliance and NCI trials. The Duke Clinical Research Institute is the largest academic clinical research organisation in the world and runs many oncology trials. Michael Kastan's DNA-damage biology and dendritic cell vaccine work under Smita Nair anchor the basic and immunology programmes.
- Neuro-oncology (Tisch Brain Tumor Center)
- Oncolytic virus immunotherapy
- Prostate cancer
- Clinical trials (DCRI)
Pages like this
not linked directly; found by shared links- PersonEvanthia Galanis
Shares Alliance for Clinical Trials in Oncology, Oncolytic viruses, Glioma & glioblastoma.
- TrialINDIGO
Shares IDH1 / IDH2, The brain: barrier and sanctuary, Glioma & glioblastoma.
- IdeaDeliver drugs and cells to the brain through the nose
Shares Oncolytic viruses, The brain: barrier and sanctuary, Glioma & glioblastoma.
- Key paperINDIGO: vorasidenib, the first targeted drug for IDH-mutant low-grade glioma
Shares IDH1 / IDH2, The brain: barrier and sanctuary, Trial design, endpoints and cost, Glioma & glioblastoma.
- InstitutionUniversity of Florida Health Cancer Center
Shares The brain: barrier and sanctuary, Glioma & glioblastoma, Prostate cancer.
- TrialHER2CLIMB-02
- IdeaA standing platform trial for every major cancer, funded as infrastructure
Shares Trial design, endpoints and cost, Glioma & glioblastoma, Prostate cancer.
- IdeaA standard platform to get drugs into the brain: focused ultrasound plus shuttle-engineered therapeutics
Shares The brain: barrier and sanctuary, HER2-positive breast cancer, Glioma & glioblastoma.